Objective. Because TNF inhibitors are not approved for persistent oligoarticular JIA (oJIA), although they are used off-label, we evaluated their effectiveness in patients in this category.
Introduction
The
International League of Associations for Rheumatology (ILAR) distinguishes oligoarticular JIA (oJIA) as one of the seven categories of JIA [1] , defining it as arthritis affecting four or fewer joints during the first 6 months of disease. Based on the number of joints affected thereafter, oJIA is subdivided into the persistent form (four or fewer joints) and the extended form (over four joints).
Persistent oJIA is a well-defined subset. Typically, it starts before the age of 6 years, and affects girls more often than boys. Patients have asymmetric arthritis, predominantly in knees and ankles. They have a high risk of chronic anterior uveitis (up to 30%), and ANAs are often present (7080%) [2] .
For many years, persistent oJIA was treated with NSAIDs and IA CS injections. In recent years a more aggressive treatment regimen has been adopted, including synthetic DMARDs, such as MTX, in order to achieve inactive disease. However, additional treatment with DMARDs does not lead to inactive disease in all patients. Figures on long-term outcome vary greatly between cohort studies [36] . Although persistent oJIA patients are thought to have the best outcome, a recent comprehensive cohort study reports 15% of patients to have joint destruction and/or visual impairment in the long term [7] .
For patients at risk, the ACR now recommends adding TNF-a-blocking agents [8] .
The TNF-a-receptor blocking agent etanercept has proved to be effective in polyarticular JIA [9, 10] . However, persistent oJIA patients have always been excluded from clinical trials. Since 2000 etanercept is registered worldwide only for refractory JIA patients with a polyarticular course. In 2008, adalimumab was registered for the same indication [11] . This monoclonal antibody against TNF-a is also used effectively for treatment of JIA-associated uveitis [12] .
As more experience is gained, TNF-a blockers are also prescribed off-label for refractory persistent oJIA. However, no detailed studies have focused on their effectiveness in this category. The present study evaluates the effectiveness of TNF-blocking agents in all Dutch persistent oJIA patients included in the Arthritis and Biologicals in Children (ABC) register. Additionally, we compared persistent oJIA patients with other patients in the register.
Methods
Data were retrieved from the ABC register, an ongoing multicentre prospective observational register that aims to include all Dutch JIA patients treated with biologic agents since 1999 to monitor effectiveness and safety [13] . In the ABC register, patient characteristics were retrieved at start and data on disease activity variables at start, at 3 months and yearly thereafter. All patients were seen regularly by their treating physician. Data were also entered at time of important events, including discontinuation or switch of biologic agents. Adverse events (AEs) and serious AEs (SAEs) were reported on a continuous basis [13, 14] . Flaring of arthritis or uveitis was regarded as a measure of treatment response. This study is embedded in the ABC register; no additional approval was needed to perform the study.
We selected patients fulfilling the ILAR criteria for persistent oJIA [1] , included in the ABC register from its foundation to February 2011. Patients without active arthritis starting biologic treatment for uveitis were not included. Patient records of persistent oJIA patients were retrospectively checked for consistency and disease flares. Of the baseline data 12.5% and of the follow-up data 14% on disease activity variables were missing {median 0 variables missing/patient [interquartile range (IQR) 03]}.
We compared baseline characteristics of persistent oJIA patients with those of other JIA patients included in our register. In this analysis, we excluded patients with systemic JIA (n = 68). We divided the non-systemic JIA patients in two groups: patients with four or fewer active joints and patients with over four active joints at start of biologic treatment.
The response to treatment was assessed with variables of the JIA core set according to an intention-to-treat analysis [15] . A modified definition of inactive disease was used: no active arthritis, no uveitis, normal ESR (values under 20 mm/h) and a physician's global assessment of disease activity <10 mm indicating no disease activity [16] . This last cut-off was chosen because we experience that physicians are reluctant to set disease activity at zero, as the disease is not cured and patients still require medication.
Descriptive statistics were reported as absolute frequencies or as medians with IQR. Fisher's exact, KruskalWallis and MannWhitney U-tests were used to perform comparisons as applicable. A P < 0.05 was considered statistically significant. SPSS version 17.0.1 was used for all analyses.
Results
Of the 408 patients included in the register until February 2011, 16 patients had persistent oJIA (3.9%). Patient and disease characteristics of patients with persistent oJIA and patients with other non-systemic JIA categories in the register are shown in Table 1 . Patients with other non-systemic JIA categories had higher disease activity and were treated more extensively than persistent oJIA patients. Persistent oJIA patients differed from the non-systemic patients with over four active joints at start, especially with regard to uveitis and ANA positivity. They resembled the patients with non-systemic JIA categories with four or fewer active joints at initiation of biologic therapy on most characteristics, extended oJIA being the most common JIA category in this group.
Most persistent oJIA patients (n = 14) started TNF inhibitors because of persistent arthritis, all started etanercept. The two patients starting adalimumab had active arthritis as well as uveitis. Median follow-up after introduction of a TNF inhibitor was 13.7 months (IQR 8.316.7 months). All patients were previously treated with MTX; nine up to a maximum dose of 515 mg/m 2 for >6 months, the other seven patients did not reach the maximum dose due to www.rheumatology.oxfordjournals.org 713 TNF-blocking agents in persistent oligoarthritis intolerance. Of these seven patients three received MTX for <6 months. Three patients were not treated with IA CSs, because of a disease course dominated by severe refractory uveitis and/or arthritis in joints less accessible for injections. The other 13 patients were treated with one or multiple injections (range 25 injections/joint). In most patients knees were involved (a total of 22 knees). Other affected joints were ankles (nine), elbows (three), fingers (three), hip (two), shoulder (one) and TM joint (one).
Eleven patients had conventional radiographs taken of the affected joints. Two patients had erosive deformities of the ankle. Two other patients had growth disturbances of the knees.
Effectiveness Table 2 shows the response to treatment in persistent oJIA patients. All disease activity variables decreased within 3 months. An even greater decrease could be seen after 15 months of follow-up. Inactive disease was reached by 10 patients (63%) within 3 months. Seven of these patients had an observed follow-up of 15 months and had by then achieved remission on medication. At 15 months, in total 9 out of 10 observed patients had achieved inactive disease. The majority of patients continued concomitant MTX. Most patients (n = 13) were not treated with IA CSs during anti-TNF treatment. Three patients received IA CSs simultaneously with the start of etanercept. These patients had been treated with IA CSs in several joints before, with insufficient response (lasting <5 months). All three patients achieved inactive disease within 3 months, which was sustained for the observed follow-up of 14 months in one patient. The other two patients had a disease flare after 10 months. One patient switched from etanercept to adalimumab and achieved inactive disease thereafter.
Two of 16 persistent oJIA patients discontinued TNF inhibitor because of disease remission after 10 months. One of these patients showed lasting remission during the observed follow-up (4 months); the other patient flared within 1 month. The other 14 patients continued using TNF inhibitor. 
Discussion
This is the first study that extensively evaluates the effectiveness of TNF blocking agents in persistent oJIA patients. Since most patients started etanercept, our results mainly reflect the effectiveness of etanercept.
After introduction of a TNF blocking agent, disease activity rapidly declined. This result was maintained and even improved after 15 months, when almost all of the patients with available follow-up had achieved inactive disease. A decrease in disease activity was found in patients included in our register comparable to that in other (non-systemic) categories of JIA [10] . One recent observational study also reports on 38 persistent oJIA patients (5% of the total studied population) being treated with etanercept. Of these oJIA patients 53% achieved inactive disease (using the modified inactive disease criteria as defined in the present study) and 13% remission on medication [17] . No additional patient or disease characteristics are described and follow-up duration of persistent oJIA patients is not provided. These combined results provide support for treatment with TNF inhibitors in some persistent oJIA patients.
Despite the fact that biologic agents were not tested in persistent oJIA patients in clinical trials, and therefore not licensed for this JIA category, paediatric rheumatologists perceived the need to prescribe TNF blocking agents to a small number of persistent oJIA patients. One might argue that this is related to the higher prevalence of uveitis in this group; another indication for biologic treatment. However, only in two patients did the presence of refractory uveitis contribute to the decision to prescribe the TNF inhibitor.
The persistent oJIA patients in our study may represent a specific oJIA subset, requiring a different treatment approach. The onset age of our patients is higher (comparable to other non-systemic JIA patients) and the prevalence of ANA is lower than in persistent oJIA patients described in the literature [2] . The categorization of JIA is subject to ongoing debate; classifying JIA by other factors than number of joints at onset has been proposed [18, 19] . The recently published ACR recommendations for management of JIA use an alternative way of categorizing: treatment choice is not purely based on JIA category, but rather on disease activity, prognostic features and response to previous therapy [8] . When applied to our study, only six patients were treated according to these recommendations. The 10 patients not fulfilling the criteria had ongoing relapsing arthritis despite use of IA CSs and DMARDs. Their scores for patient/parent assessments of pain and well-being were identical to other non-systemic JIA patients treated with TNF inhibitors. It seems that these recommendations are not fully applicable in daily practice. A reason to be reticent with prescribing TNF inhibitors to persistent oJIA patients may be a safety concern. In this study, insufficient patient-years are observed to be able to evaluate the safety of TNF inhibitors. Although TNF blockers are observed to be well tolerated in previous reports on patients with all JIA categories [10, 20] , there is still insufficient knowledge about the long-term effects. Balancing the risks and benefits remains important when considering treatment with TNF blockers.
The present study has some limitations: the small number of patients and the short follow-up duration. The 16 patients included in this study were the only persistent oJIA patients in the Netherlands initiating TNF blocking agents since its introduction. To our knowledge this is the largest case series to date reporting detailed information on persistent oJIA patients only.
We further chose not to use the ACR Pedi 30, 50, 70 response criteria, which in our opinion are more appropriate for polyarticular disease. They do not capture the full degree of change in disease activity when individual baseline variables are low, as is the case in persistent oJIA. Today no specific instrument evaluating oligoarticular patients is available; therefore, the response to treatment was evaluated by change on the single core-set disease activity variables and the composite score for inactive disease.
Three of our patients were treated with IA CSs at start of etanercept and subsequently achieved inactive disease within 3 months. This inevitably results in a biased evaluation of response to the newly introduced TNF inhibitor. However, this is inherent to the nature of the current study and reflects daily clinical practice.
In conclusion, the results suggest that TNF blockers are effective in persistent oJIA patients who were refractory to MTX treatment and IA CS injections. Persistent oJIA patients treated with TNF inhibitors resemble other non-systemic JIA patients from our register with regard to age at onset and certain measures of disease activity. In these more severely affected persistent oJIA patients treatment with TNF inhibitors is a justifiable option.
Rheumatology key messages
. Although not approved for this indication TNF inhibitors are prescribed in persistent oJIA. . TNF inhibitors are as effective in persistent oJIA as in polyarticular JIA.
